Back to Research

Organization profile

Navignostics

Navignostics AG is a Swiss precision oncology company specializing in spatial single-cell proteomics to guide personalized cancer treatment. A spin-off from the University of Zurich, it analyzes tumor samples to provide clinicians and pharmaceutical researchers with deep biological insights into cell composition and resistance mechanisms.

Horgen, SwitzerlandFounded 2022

Overview

1. Executive Summary (Confidence: High)

Navignostics is a high-growth precision medicine company that is revolutionizing cancer diagnostics through the application of spatial single-cell proteomics. Founded in 2022 as a spin-off from the University of Zurich’s Bodenmiller Lab, the company provides a paradigm shift from traditional "bulk" sequencing to high-resolution protein imaging. By determining the exact cellular composition and interactions within a single tumor tissue section, Navignostics identifies the optimal therapy for individual patients, particularly those in late-stage settings where standard treatments have failed. The company’s clinical utility was validated in 2025 by a landmark Nature Medicine study showing that its profiling technology tripled the disease control rate for heavily pretreated melanoma patients. With a CHF 7.5 million seed round led by Bruker and a strategic partnership with Standard BioTools, Navignostics is scaling toward global distribution by early 2026.18

Unlock the full profileGet the complete company dossier

This public view only shows an extract. Open the full profile to access the complete company intelligence record, including the full write-up and structured research details.

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.